Warning letter
Nartex Laboratorios Homeopaticos S.A. de C.V.: warning letter of Nov 4, 2020
FDA warning letter 608540 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 608540 |
|---|---|
| Company | Nartex Laboratorios Homeopaticos S.A. de C.V. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 4, 2020 |
| Posted date | Nov 10, 2020 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(2), 211.100(a) |
| Inspection city | Torreon |
| Inspection start date | Feb 24, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: